Using immunocytochemical analysis, protein expressions of vimentin (Vim) and somatostatin receptor 2A (SSTR2A) were observed in these two primary benign meningioma cells (WHO grade I) including the well-established meningioma cell lines—HKBMM and IOMM-Lee (WHO grade III). This evidence concerns the gene VIM and benign meningioma.